The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia ; volume:8 ; number:1 ; day:22 ; month:11 ; year:2017 ; pages:1-12 ; date:12.2017
Nature Communications ; 8, Heft 1 (22.11.2017), 1-12, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Di Tullio, Alessandro
- Beteiligte Personen und Organisationen
-
Rouault-Pierre, Kevin
Abarrategi, Ander
Mian, Syed
Grey, William
Gribben, John
Stewart, Aengus
Blackwood, Elizabeth
Bonnet, Dominique
SpringerLink (Online service)
- DOI
-
10.1038/s41467-017-01834-4
- URN
-
urn:nbn:de:1111-201804016709
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Di Tullio, Alessandro
- Rouault-Pierre, Kevin
- Abarrategi, Ander
- Mian, Syed
- Grey, William
- Gribben, John
- Stewart, Aengus
- Blackwood, Elizabeth
- Bonnet, Dominique
- SpringerLink (Online service)
Ähnliche Objekte (12)
MLKL promotes cellular differentiation in myeloid leukemia by facilitating endosomal secretion of G-CSF
Correction: MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Growth Factors G-CSF and GM-CSF : Clinical Options
Mechanisms of immunomodulation by G-CSF
Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
Der Wirkstoff Filgrastim : G-CSF als Biosimilar
Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
MLKL promotes cellular differentiation in myeloid leukemia by facilitating endosomal secretion of G-CSF
Correction: MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Growth Factors G-CSF and GM-CSF : Clinical Options
Mechanisms of immunomodulation by G-CSF
Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
Der Wirkstoff Filgrastim : G-CSF als Biosimilar
Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
MLKL promotes cellular differentiation in myeloid leukemia by facilitating endosomal secretion of G-CSF
Correction: MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Growth Factors G-CSF and GM-CSF : Clinical Options
Mechanisms of immunomodulation by G-CSF
Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
Der Wirkstoff Filgrastim : G-CSF als Biosimilar
Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia